Which CLL patients would benefit from intensive therapy?
AML17 trial update: FLT3-ITD mutation and daunorubicin dosage
Re-analysis of RESONATE-2 trial of ibrutinib vs chlorambucil in CLL
Reporting positive treatment outcomes with bendamustine + rituximab in indolent lymphomas
Mathias J Rummel
GVHD: helping patients cope with the side effects of transplantation